NUEVA YORK – The pharmaceutical company Pfizer and its German company BioNTech, which were vaccinated against the coronavirus as the first to receive authorization for emergency use in the United States, applied for permission to apply to more adolescents.
The companies have applied to the Food and Drug Administration of the United States (FDA for its flags in English) which extends the authorization for the use of their vaccine to include adolescents between 12 and 15 years of age. In December, the use of emergency doses of two doses for people aged 16 and over was authorized.
BREAK: Today, with @BioNTech_Group, we have submitted a request to the US FDA to extend the emergency use of our COVID-19 vaccine to teenagers aged 12 to 15 years. pic.twitter.com/AHjc2khnUj
– Pfizer Inc. (@pfizer) 9 April 2021
Pfizer and BioNTech are working treacherously with the FDA and regulators of other nations to issue a conditional emergency permit that is most suitable for adolescents 12 to 15 years of age.
Both companies underwent a communication in which the preliminary results are due on March 31 of the clinical trials in this demonstrated group that the vaccine is safe and 100% effective in preventing infections. It seems that the collateral effects coincide with the tests with volunteers from 16 to 25 years: pain and inflammation in the place of injection, fatigue, pain, fever and nausea.
Pending a regulatory decision, we are hoping to make this vaccine available to the 12-15 age group before the start of the school year 2021.
– Pfizer Inc. (@pfizer) 9 April 2021
All participants in the study, volunteers from 12 to 15 years of age, will be under observation during these years as long as the second dose is given to follow up on any problem of inactivity and determine the time to protect the vaccine.
